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Introduction
Bone remodeling is a process of continuous resorption and neo-
synthesis of bone that determines bone structure and quality 
during adult life. Osteoblasts, the bone-forming cells, can regu-
late osteoclast formation by expressing the negative regulator 
osteoprotegerin (OPG) or positive regulators, such as receptor 
activator of NF-B ligand (Rankl) and macrophage colony–
stimulating factor 1 (Teitelbaum and Ross, 2003; Takeda and 
Karsenty, 2008). Imbalances in bone remodeling can result in 
severe perturbations in skeletal structure and function, leading 
to conditions such as osteoporosis, osteosclerosis, and osteo-
petrosis. Osteoporosis is a bone disease in which the bone mineral 
density is reduced, the bone microarchitecture is disrupted, and 
the amount of noncollagenous proteins in bone is altered, lead-
ing to an increased risk of fractures (Chien and Karsenty, 2005). 
Osteopetrosis is a disease in which the bones are more brittle 
as a result of decreased osteoclast function despite increased 
bone mass (Rodan and Martin, 2000). In contrast, osteosclero-
sis is a bone disorder characterized by an abnormal hardening 
and progressive increase in bone mass of the skeleton, result-
ing from increased bone formation (Rodan and Martin, 2000).   
Unlike osteopetrosis, the primary defect of this disorder, caus-
ing increased bone mass, results from altered osteoblast function. 
Several soluble molecules and transcription factors, including 
Ihh, FGF18, Runx2, and osterix (Osx), regulate osteoblast differ-
entiation (Karsenty and Wagner, 2002). However, the transcrip-
tional mechanisms responsible for the expression of bone-specific 
genes, in particular extracellular matrix components, are still 
not fully understood.
The activator protein-1 (AP-1) transcription factor com-
plex consists of a large variety of dimers composed of members 
of the Fos, Jun, and activating transcription factor (ATF) fami-
lies (Wagner and Eferl, 2005). AP-1 activity is implicated in a 
wide range of biological processes, and AP-1 proteins have im-
portant roles as regulators of bone development. Loss- and gain-
of-function mutations in mice of Fos members, and to a lesser 
extent of Jun and ATF members, most notably affect chondro-
cyte, osteoblast, and osteoclast physiology, resulting in a variety 
of pathological skeletal conditions (Wagner and Eferl, 2005). 
Chondrocyte-specific inactivation of c-Jun leads to severe scoliosis 
T
he  activator  protein-1  (AP-1)  transcription  factor 
complex, in particular the Fos proteins, is an impor-
tant regulator of bone homeostasis. Fra-2 (Fosl2),   
a Fos-related protein of the AP-1 family, is expressed in 
bone cells, and newborn mice lacking Fra-2 exhibit de-
fects in chondrocytes and osteoclasts. Here we show that 
Fra-2–deficient osteoblasts display a differentiation defect 
both in vivo and in vitro. Moreover, Fra-2–overexpressing 
mice are osteosclerotic because of increased differentia-
tion of osteoblasts, which appears to be cell autonomous. 
Importantly, the osteoblast-specific osteocalcin (Oc) gene 
and collagen12 (col12) are transcriptional targets of 
Fra-2 in both murine and human bone cells. In addition, 
Fra-2, Oc, and col1 are expressed in stromal cells of human 
chondroblastic and osteoblastic osteosarcomas (Os’s) as 
well as during osteoblast differentiation of human Os cell 
lines. These findings reveal a novel function of Fra-2/AP-1 
as a positive regulator of bone and matrix formation in mice 
and humans.
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We next performed molecular analyses of osteoblast markers 
by quantitative PCR (qPCR) and in situ hybridization using 
Fosl2
/ newborn mice. Increased expression of osteopontin 
(Opn), an early osteoblast, late chondrocyte, but also osteo-
clast marker, was observed in Fosl2 ko bone at P2 (day 2   
after  birth).  Moreover,  a  reduction  of  Runx2,  bone  sialo­
protein (Bsp), col12, and Oc expression, late markers of osteo-
blast function, was observed (Fig. 1 B). Osteoblast marker 
genes, such as ATF­4, osteonectin, Osx, OPG, Rankl, col11, 
and matrix gla­protein (Mgp), were unaffected (Fig. 1 B). 
Consistent with lower Oc expression, Oc secretion was also 
significantly  reduced  in  sera  from  P2  pups  (unpublished 
data). The increase in Opn mRNA levels and the reduction of 
Runx2, Bsp, col12, and Oc mRNA expression were con-
firmed by in situ hybridization (Fig. 1 C). As osteoblasts and 
adipocytes are derived from common progenitor cells, we 
quantified the numbers of adipocytes in Fosl2
/ and Fosl2
+/+ 
long bones at P2. No significant changes between the two 
genotypes were observed (Fig. 1 D). Next we analyzed early 
and late adipocyte markers by qPCR to assess a potential   
differentiation defect. Adipocyte protein (Ap­2), preadipo­
cyte  factor  1  (Pref1),  and  glucose  transporter  4  (Glut4) 
mRNA  were  found  to  be  unaffected.  However,  CCAAT/
enhancer  binding  protein­  (CEBP­),  CCAAT/enhancer 
binding protein­ (CEBP­), and peroxisome proliferator­
activated receptor­ (PPAR­) mRNA expression was increased 
(Fig. 1 E), suggesting an effect on adipocyte differentiation   
in vivo.
Osteoblast differentiation defects in the 
absence of Fra-2 in vitro
To  investigate  a  possible  cell-autonomous  defect  leading  to   
osteopenia in Fosl2 ko pups, the activity of osteoblasts was ana-
lyzed in vitro. Primary osteoblasts were prepared from calvariae 
of neonatal mice and differentiated in vitro. Staining for osteo-
blast differentiation markers, such as AP, revealed no major dif-
ferences in Fosl2 ko cells (unpublished data). The activity of 
osteoblasts was next analyzed by the deposition of mineralized 
extracellular matrix. The deposition of mineralized extracellu-
lar matrix was reduced as shown by Alizarin red staining and by 
quantification of the number of mineralized nodules (Fig. 2 A). 
Similar results were observed when osteoblasts were differenti-
ated from bone marrow stromal cells. Importantly, Oil red O 
staining for mature adipocytes and quantification of the number 
of adipocytes revealed a significant increase in Fosl2 ko cells 
(Fig.  2 A).  Interestingly,  expression  levels  of  transcripts  for 
Runx2, col12, and Oc were decreased at day 10 and 15 in 
Fosl2 ko cells, whereas mRNA expression for ATF­4, Osx, and 
col11 was unaffected (Fig. 2 B). Moreover, the collagen con-
tent was found to be decreased in conditioned medium from 
Fosl2 ko cultures (Fig. 2 C). Consistent with the increased num-
bers of mature adipocytes in Fosl2 ko cells, adipocyte markers 
such  as  Ap2,  Pref1,  CEBP­,  CEBP­,  and  PPAR­  were   
increased in Fosl2 ko cells, whereas Glut4 expression was un-
affected (Fig. 2 B). The proliferation rate of Fosl2 ko calvarial   
osteoblasts, determined by BrdU incorporation, was increased 
by 50% after 2 d of culture (Fig. 2 D), and growth curve analysis   
caused by failure of intervertebral disc formation, suggesting 
that c-Jun is a regulator of sclerotomal differentiation (Behrens 
et al., 2003). Moreover, c­Jun is essential for efficient osteoclasto-
genesis (David et al., 2002), whereas conditional loss of JunB 
results in severe osteopenia because of cell-autonomous osteo-
blast and osteoclast defects (Kenner et al., 2004). Mice lacking 
JunD  exhibit  increased  bone  mass  as  a  result  of  increased   
bone formation (Kawamata et al., 2008). Mice carrying a germ-
line mutation in ATF-2 display defects in endochondral ossifica-
tion at epiphyseal plates similar to human hypochondroplasia 
(Reimold et al., 1996). In addition, ATF-4 was identified as   
a critical regulator of osteoblast function. It is required for   
osteoblast-specific  expression  of  osteocalcin  (Oc)  and  for   
posttranscriptional regulation of type I collagen (col1) syn-
thesis, the main constituents of bone matrix, as well as for 
transcriptional control of Rankl expression (Yang et al., 2004; 
Elefteriou et al., 2005).
Detailed analyses of transgenic (tg) mice overexpressing 
Fos proteins have underlined the important functions of Fos/
AP-1 in osteoblasts. Fos overexpression leads to osteosarcomas 
(Os’s), a bone tumor characterized by transformation of cells   
of the osteoblastic lineage (Grigoriadis et al., 1993). Moreover, 
mice  overexpressing  either  the  Fos  target  gene,  Fra-1,  also 
known as Fos­like antigen 1 (Fosl1), or the short isoform of 
FosB, FosB, develop osteosclerosis as a result of enhanced 
osteoblast differentiation (Jochum et al., 2000; Sabatakos et al., 
2000; Kveiborg et al., 2002). We have previously shown that 
mice lacking Fra-2 (Fos­like antigen 2 [Fosl2]) display deficien-
cies in chondrocytes (Karreth et al., 2004). In addition, in the 
absence of Fra-2, the survival of osteoclasts is affected, leading 
to the formation of giant osteoclasts by a novel pathway (Bozec 
et al., 2008).
The function of Fra-2 in bone-forming osteoblasts was 
analyzed in postnatal development and adult bones using Fosl2 
knockout (Fosl2 ko or Fosl2
/) pups and Fosl2 tg mice (Karreth 
et al., 2004; Bozec et al., 2008; Eferl et al., 2008). The Fosl2 tg 
mice develop pulmonary fibrosis around 16 wk of age caused 
by vascular remodeling and subsequent pulmonary fibrosis 
(Eferl et al., 2008). Interestingly, Fosl2 tg mice also develop an 
osteosclerotic phenotype as early as 4 wk of age by affecting 
osteoblast differentiation in vivo and in vitro. Moreover, Fosl2
/ 
osteoblasts fail to differentiate in vitro and acquire an adipo-
genic phenotype. At the molecular level, we demonstrate that in 
both mouse and human bone cells, osteoblast differentiation is 
affected likely as a result of reduced expression of collagen12 
(col12) and Oc, which are shown to be direct transcriptional 
targets of Fra-2.
Results
Fosl2 ko pups are osteopenic
To obtain functional data for a role of Fra-2 in osteoblasts, 
Fosl2 ko pups were analyzed (Karreth et al., 2004; Eferl et al., 
2007; Bozec et al., 2008). Von Kossa staining and quantitative 
histomorphometry revealed a 50% decrease of mineralized 
bone as well as a 40% decrease in calvarial thickness, whereas 
osteoblast numbers were not altered (Fig. 1 A; Bozec et al., 2008). 1095 Fra-2/AP-1 and bone mass regulation • Bozec et al.
Figure 1.  Fosl2 ko pups exhibit an osteopenic phenotype. (A) Von Kossa staining of calvaria at P3. Quantification of bone volume calvaria thickness   
(P3; Fosl2
+/+, n = 7; Fosl2
/, n = 6). (B) qPCR analyses of Runx2, ATF-4, osteopontin (Opn), osteonectin (On), osterix (Osx), osteoprotegerin (OPG), recep-
tor activator of NF-B ligand (Rankl), bone sialoprotein (Bsp), matrix gla-protein (Mgp), collagen 12 (col12), collagen 11 (col11), and osteocalcin 
(Oc) in Fosl2
+/+ and Fosl2
/ total long bone mRNA at P2. 4.6 represents the relative expression of Opn in Fosl2
/ long bone. (C) In situ hybridization 
for Runx2, Opn, Bsp, col12, and Oc on P2 long bones. (D) Quantification of adipocyte numbers (Nat/MaAr) in Fosl2
+/+ and Fosl2
/ total long bones 
(P3; Fosl2
+/+, n = 7; Fosl2
/, n = 6). (E) qPCR analyses of Adipocyte protein (Ap-2), preadipocyte factor 1 (Pref1), CCAAT/enhancer binding protein- 
(CEBP-), CCAAT/enhancer binding protein- (CEBP-), peroxisome proliferator-activated receptor- (PPAR-), and glucose transporter 4 (Glut4) in Fosl2
+/+ 
and Fosl2
/ total long bone mRNA at P2. Error bars represent mean values ± SD, and wt is set to *, P < 0.01; Fosl2
+/+, n = 4 and Fosl2
/, n = 6.   
Bars, 500 µm.JCB • VOLUME 190 • NUMBER 6 • 2010   1096
TUNEL assay after 2 d of culture (Fig. 2 D). These findings in-
dicate that Fra-2 controls osteoblast differentiation and matrix 
expression in a cell-autonomous manner.
showed that cell density and proliferation capacity were slightly 
increased in Fosl2 ko cells (Fig. 2 E). No difference was   
observed regarding apoptosis of osteoblasts as determined by 
Figure 2.  Osteoblast differentiation of Fosl2 ko cells in vitro. (A) Alizarin red and Oil red O/hematoxylin staining of calvaria-derived osteoblasts isolated 
from Fosl2
+/+ and Fosl2
/ pups. Cells were cultured for 15 d on plastic in the presence of -glycerophosphate and ascorbic acid. Quantification of the 
number of nodules and adipocytes per well is shown. Arrows indicate adipocytes. Bars, 200 µm. (B) qPCR analyses of osteoblast markers (Runx2, ATF-4, 
osterix [Osx], collagen 11 [col11], collagen 12 [col12], and osteocalcin [Oc]) and adipocyte markers (Ap2, Pref1, CEBP-, CEBP-, PPAR-, and 
Glut4 in Fosl2
+/+ and Fosl2
/ cells at day 15 of differentiation; n = 3). Values are presented as relative expression, and wt is set to 1. (C) Collagen content 
in Fosl2
+/+ and Fosl2
/ osteoblast–conditioned medium at day 0, 5, 10, and 15 of differentiation (n = 3). (D) BrdU incorporation and TUNEL-positive cells 
of calvaria-derived osteoblasts isolated from Fosl2
+/+ and Fosl2
/ pups. (E) Cumulative cell number (proliferation) of Fosl2
+/+ and Fosl2
/ osteoblasts.   
*, P < 0.01; n = 3. Error bars represent mean values ± SD.1097 Fra-2/AP-1 and bone mass regulation • Bozec et al.
positively regulates the bone-forming activity of osteoblasts 
in a cell-autonomous manner.
Col12 and Oc are direct transcriptional 
targets of Fra-2 in osteoblasts
The  decreased  expression  of  Oc  and  col12  expression  in 
Fosl2 ko newborn osteoblasts and the corresponding increased 
expression in Fosl2 tg osteoblasts suggested that these genes 
may be direct transcriptional targets of Fra-2. To assess Fra-2 
binding to the Oc promoter, chromatin immunoprecipitation 
(ChIP)  analysis  was  performed  using  Fra-2  antibodies  on 
Fosl2 control and ko primary osteoblasts. Specific primer pairs 
were used to amplify DNA fragments containing the OSE1 
binding site in the Oc promoter, which has been shown to bind 
ATF-4 (Yang et al., 2004). As shown in Fig. 5 A, a Fra-2 anti-
body specifically immunoprecipitated the Oc promoter frag-
ment from wt osteoblast chromatin extracts but not from Fosl2 
ko cells. No binding of other AP-1 members, such as Fra-1,   
c-Fos,  c-Jun,  JunB,  and  JunD,  to  the  Oc  promoter  could   
be detected (unpublished data). Moreover, in the absence of   
Fra-2, ATF-4 binding to the same site was decreased by 50%. 
This was not the result of a decrease in ATF-4 protein levels 
because binding of ATF-4 to the promoter of another target 
gene, Rankl (Elefteriou et al., 2005), was unchanged in Fosl2 
ko cells as well as total ATF-4 protein (Fig. 5, A and B). Inter-
estingly, Fra-2 was not able to bind the Rankl promoter, con-
sistent with unaltered expression of Rankl in Fosl2 ko cells, 
indicating that the interaction of Fra-2 with ATF-4 was proba-
bly specific for the Oc promoter. Moreover, immunoprecipitation 
assays in primary osteoblasts showed that Fra-2 and ATF-4 were 
able to interact (Fig. 5 B).
Additional ChIP assays were performed with antibodies 
directed against methylated histone H3 to analyze chromatin 
modifications on the Oc promoter (Fig. 5 C). ChIP and subse-
quent qPCR analyses of the Oc promoter revealed low levels 
of active (H3K4me3) and repressive (H3K27me3) methylation 
marks in control cells, consistent with a low transcriptional ac-
tivity of Oc in exponentially growing osteoblasts. However, a 
striking increase in repressive methylation marks was observed 
in Fosl2 ko osteoblasts, suggesting that the absence of Fra-2 
leads to a decreased Oc promoter activity marked by the recruit-
ment of repressive methylation marks (Fig. 5, H3K27me3). No 
changes in methylation marks in the Rankl promoter were ob-
served between the two genotypes, consistent with the fact that 
Rankl expression is unaffected in the absence of Fra-2 (Fig. 5 C).   
Moreover, in DNA cotransfection experiments, ATF-4 and Fra-2 
expression vectors, as well as a combination of both, increased 
the activity of a luciferase reporter containing the Oc promoter 
(pOG2) fragment (Fig. 5 D). This was not observed with the 
mutated  form  of  the  Oc  promoter  (pOG2-MUT;  Fig.  5  D).   
Activation of the Oc promoter by DNA cotransfection experi-
ments after Fra-2–specific silencing in primary osteoblasts was 
performed next. Fra-2 and ATF-4 trans-activated the Oc pro-
moter. Because of the 25% remaining Fra-2 mRNA, low levels 
of Fra-2 might be sufficient for activation of the promoter by 
ATF-4 alone (Fig. S2 B). Importantly, an ATF-4–Fra-2 forced 
dimer (Bakiri et al., 2002) efficiently trans-activated the same 
Fosl2 tg mice are osteosclerotic and 
exhibit altered matrix protein expression
To assess a potential direct effect of Fra-2 on bone-forming 
cells in adult mice in vivo, histomorphometric and molecular 
analyses were performed on Fra-2–overexpressing mice (Eferl 
et al., 2008). No obvious phenotype was observed in Fosl2 tg 
newborns (unpublished data). The bone volume was similar be-
tween wild-type (wt) and mutant mice until 2 wk of age, whereas 
4-wk- and 3-mo-old mice exhibited an increased bone volume 
as shown by microcomputed tomography (micro-CT) analysis 
(Fig. 3, A and B). Histomorphometric analyses on Fosl2 tg and 
control mice at two different time points (4 wk and 3 mo) revealed 
that bone volume, bone formation, and bone surface were increased 
in Fosl2 tg mice (Fig. 3 B). The number of osteoblasts was sig-
nificantly increased only in 4-wk-old, but not in 3-mo-old, mice 
(Fig. 3 B). Interestingly, the number of adipocytes was significantly 
decreased in Fosl2 tg long bones compared with controls at 3 mo of 
age (Fig. 3 B and Fig. S1 A). Importantly, osteoclast activity, num-
bers, and size were unchanged as shown by CTx measurements, 
tartrate-resistant acid phosphatase (TRAP) staining, and histomor-
phometric analyses (Fig. S1, B and C). Moreover, in vitro osteo-
clast differentiation revealed no difference on plastic or on dentine 
slices between control and Fosl2 tg cells. The activity of osteoclasts 
in vitro was increased as shown by resorption markers such as 
TRAP, CathK, MMP9, CaII, and Nfatc1 (Fig. S1 D). This result is 
characteristic of an osteosclerotic phenotype accompanied by in-
creased function or differentiation of osteoblasts. Consistent with 
lower expression of col12 and Oc in Fosl2 ko long bones, in-
creased expression levels of col12 and Oc mRNA were observed 
in Fosl2 tg long bones from 4-wk- and 3-mo-old mice (Fig. 3,   
C and D). No differences in the levels of Opn and Runx2 mRNA 
were observed, whereas these markers were affected in Fosl2 ko 
long bones. At 3 mo, the level of OPG mRNA was decreased, and 
the level of Rankl mRNA was increased in Fosl2 tg long bones 
(Fig. 3, C and D). However, the levels of OPG and Rankl were un-
affected in sera from 3-mo-old Fosl2 tg mice (Fig. 3 E). Next, the 
mRNA levels of adipocyte markers were measured. No difference 
in the levels of Pref1, CEBP­, CEBP­, and Glut4 mRNA was 
observed, although the levels of Ap2 and PPAR­ mRNA were   
decreased in 3-mo-old Fosl2 tg long bones (Fig. 3 F).
Enhanced osteoblast differentiation of 
Fosl2 tg cells in vitro
The cell-autonomous effect of Fra-2 in osteoblast differen-
tiation was next analyzed in Fosl2 tg calvarial osteoblasts. 
Increased  deposition  of  mineralized  extracellular  matrix 
and reduced differentiation into adipocytes were observed 
in Fosl2 tg compared with control cells (Fig. 4 A). Runx2, 
col12, and Oc mRNA expression was strongly increased at 
10 and 15 d of culture, whereas no differences in the RNA 
levels  of  ATF­4,  Osx,  and  col11  were  observed,  similar 
to Fosl2 ko cells (Fig. 2 B vs. Fig. 4 B). The expression of   
adipocyte markers Ap2, Pref1, CEBP­, and PPAR­ was 
consistently reduced, whereas the expression of CEBP­ and 
Glut4 was unchanged (Fig. 4 B). Collagen content measured 
in conditioned medium from Fosl2 tg cells was increased at 
day 5, 10, and 15 of differentiation (Fig. 4 C). Thus, Fra-2 JCB • VOLUME 190 • NUMBER 6 • 2010   1098
Figure 3.  Fosl2 tg mice are osteosclerotic. (A) Micro-CT and von Kossa staining of spines at 3 mo. Bar, 500 µm. (B) Quantification of bone volume   
(BV/TV), osteoblast number (Nob/BPm), adipocyte number (Nat/MaAr), bone formation rate (BFR/BS), and bone surface (MS/BS) at 2 wk (n = 4), 4 wk 
(n = 6/8), and 3 mo (n = 5/8). (C and D) qPCR analyses of Runx2, ATF-4, osteopontin (Opn), osteonectin (On), osterix (Osx), osteoprotegerin (OPG), 
receptor activator of NF-B ligand (Rankl), bone sialoprotein (Bsp), matrix gla-protein (Mgp), collagen 12 (col12), collagen 11 (col11), and osteo-
calcin (Oc) in Fosl2
+/+ and Fosl2 tg total long bone mRNA at 4 wk (C) and 3 mo (D). wt is set to 1. *, P < 0.01; n = 5. (E) OPG and Rankl levels in sera 
from Fosl2 wt and tg mice at 3 mo of age (n = 7). The ratio between OPG and Rankl is shown in the third graph. (F) qPCR analyses of Adipocyte protein 
(Ap-2), preadipocyte factor 1 (Pref1), CCAAT/enhancer binding protein- (CEBP-), CCAAT/enhancer binding protein- (CEBP-), peroxisome proliferator-
activated receptor- (PPAR-), and glucose transporter 4 (Glut4) in Fosl2
+/+ and Fosl2 tg total long bone mRNA at 3 mo of age. Error bars represent mean 
values ± SD, and wt is set to *, P < 0.01; n = 6.1099 Fra-2/AP-1 and bone mass regulation • Bozec et al.
(proximal) and revealed two additional TRE-like elements lo-
cated at positions 850 and 890 bp (distal) upstream of the 
transcriptional start site. A DNA fragment containing these 
two TRE-like elements could be specifically amplified from 
Fosl2 control, but not from Fosl2 ko immunoprecipitates, indi-
cating that an AP-1 complex containing Fra-2 is present on the 
col12 promoter (Fig. 5 E). The potential Fra-2 binding part-
ner was next investigated, and ChIP analysis of the same frag-
ment was performed using Fosl2 control and ko osteoblasts with   
reporter, suggesting that Fra-2 and ATF-4 might function as   
heterodimers (Fig. 5 D).
Previous studies have indicated a role for AP-1 in medi-
ating the basal and TGF-–induced transcription of the mouse 
col12 gene (Chang and Goldberg, 1995), and one AP-1 bind-
ing sequence has been identified in the human a2(I) collagen 
(COL1A2) promoter (Chung et al., 1996). A close comparative 
inspection of the mouse and rat col12 promoters indicated 
that this sequence was almost conserved at position 253 bp 
Figure 4.  Osteoblast differentiation of Fosl2 tg cells in vitro. (A) Alizarin red and Oil red O/hematoxylin staining of calvaria-derived osteoblast isolated 
from Fosl2
+/+ and Fosl2 tg pups. Cells were cultured for 15 d on plastic in the presence of -glycerophosphate and ascorbic acid. Quantification of the 
number of nodules and adipocytes per well is shown. Arrows indicate adipocytes. n = 3. Bar, 200 µm. (B) qPCR analyses of Runx2, ATF-4, osterix (Osx), 
collagen 11 (col11), collagen 12 (col12), and osteocalcin (Oc) in Fosl2
+/+ and Fosl2 tg cells at day 15 of differentiation (n = 3). Values are presented 
as relative expression, and wt is set to 1. (C) Collagen content in Fosl2
+/+ and Fosl2 tg osteoblast–conditioned medium at day 0, 5, 10, and 15 of dif-
ferentiation (n = 3). Error bars represent mean values ± SD. *, P < 0.01.JCB • VOLUME 190 • NUMBER 6 • 2010   1100
Figure 5.  Oc and col12 are transcriptional target genes of Fra-2. (A) ChIP for Oc and Rankl promoter. Arrows indicate primers amplifying fragments. 
Chromatin of the indicated genotypes was immunoprecipitated with AP-1 antibodies. Quantification and endpoint qPCR-amplified fragments at 200 bp are 
shown. *, P < 0.01. (B) Coimmunoprecipitation for Fra-2 and ATF-4 in primary wt osteoblasts. IgG is used for loading control. Western blot analyses for 
38 kD ATF-4 in Fosl2
+/+ (n = 2) and Fosl2
/ (n = 3) long bones at P2. 42 kD actin is used as loading control. (C) H3K4me3 and H3K27me3 ChIP on Oc 
and Rankl promoter. Chromatin from osteoblasts of the indicated genotypes was immunoprecipitated with H3K4me3- and H3K27me3-specific antibodies. 
Bars represent qPCR quantification relative to input chromatin. (D) wt (pOG2-luc) or Ap-1 mutated (pOG2-MUT-luc) reporter assay for the Oc promoter 
fragment in the presence of ATF-4, Fra-2, ATF-4 + Fra-2, and ATF-4–Fra-2 expression vectors (n = 3). (E) ChIP for col12 promoter. Arrows indicate primers 
amplifying fragments at 200 bp. Chromatin of the indicated genotypes was immunoprecipitated with AP-1 antibodies. Endpoint qPCR-amplified fragments 
are shown. (F) H3K4me3 and H3K27me3 ChIP on col12 promoter. Chromatin from osteoblasts of the indicated genotypes was immunoprecipitated 
with H3K4me3- and H3K27me3-specific antibodies. Bars represent qPCR quantification relative to input chromatin. (G) pH5-luc, pH6-luc, and pH10-luc 
reporter assay for the col12 promoter fragment in the presence of Fra-2, c-Jun, JunB, c-Jun–Fra-2, and JunB–Fra-2 expression vectors (n = 3). Error bars 
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different Jun and ATF-4 antibodies. Whereas c-Jun and JunB 
were clearly bound to the col12 promoter in wt cells, no bind-
ing of c-Jun or JunB could be detected in the absence of Fra-2, 
indicating that, at least in osteoblasts, c-Jun and JunB can only 
bind to this putative AP-1 element as heterodimers with Fra-2. 
Interestingly, in the absence of Fra-2, c-Fos and ATF-4 are 
specifically recruited to this site (Fig. 5 E). In the col12 pro-
moter, a dramatic decrease in active (H3K4me3) methylation 
marks was observed in primary Fosl2 ko osteoblasts, which 
correlated with a striking increase in repressive (H3K27me3) 
methylation marks, indicating that in the absence of Fra-2, the 
col12 promoter was less active (Fig. 5 F). Lastly, luciferase 
reporter assays using col12 promoter (pH5-luc, 2,000–0 bp; 
pH6-luc, 350–0 bp; and pH10-luc, 108–0 bp) revealed that   
c-Jun, JunB, and Fra-2 expression vectors, as well as a combina-
tion of both c-Jun + Fra-2 or JunB + Fra-2, increased the activity of 
a pH5-luc promoter containing the 2,000–0 bp of the col12 
promoter (Fig. 5 G). Moreover, luciferase reporter assays per-
formed in primary osteoblasts revealed that the increased ac-
tivity observed for c-Jun, JunB, and Fra-2 expression vectors 
in wt cells was slightly decreased in Fra-2 knockdown osteo-
blasts (Fig. S2 C). ATF-4 and c-Fos expression vectors were 
unable to activate the col12 promoter as efficiently as Fra-2 
(Fig. S2 C). Forced dimers of c-Jun–Fra-2 or JunB–Fra-2   
efficiently trans-activated the same reporter, suggesting that 
Fra-2 and c-Jun or Fra-2 and JunB were acting as heterodimers   
(Fig. 5 G).
These findings, together with the altered expression of Oc 
and col12 observed in Fosl2 ko and tg mutants, indicate that 
both genes are direct transcriptional targets of Fra-2 in vivo. 
Fra-2–ATF-4 dimers and Fra-2 dimers with c-Jun and JunB 
positively regulate Oc and col12 transcription, respectively.
Fra-2 affects matrix protein expression 
and osteoblast differentiation in human 
bone cells
To investigate the relevance of our findings to human bone cells, 
expression analyses of Fra-2, col1, and Oc were performed by 
immunohistochemistry using bone and cartilage tumor tissue 
arrays with unmatched normal adjacent tissues (24 cases). The 
normal tissue, when stained for Fra-2, col1, and Oc, revealed a 
common expression pattern in human stromal cells (Fig. 6 A). 
Moreover, Fra-2, col1, and Oc were also found expressed in 
stromal cells of chondroblastic Os’s, osteoblastic Os’s, chondro-
sarcomas, giant cell tumors, fibroblastic Os’s, and mesenchy-
mal chondrosarcomas (Fig. 6 A and Fig. S3 B). The localization 
of stromal cells was determined by hematoxylin and eosin (H&E) 
staining on serial sections from identical human samples (Fig. S3, 
A and B).
To validate these in vivo observations, the consequences 
of down-regulation of Fra-2 using an in vitro short hairpin RNA 
(shRNA) approach was analyzed in three different human Os 
cell lines: U2Os, sarcoma osteogenics (SAOs), and Cal72. As 
previously described, these cell lines have a different genetic 
background, including the p53 status, although all have molecu-
lar characteristics common to an osteoblastic phenotype (Rochet 
et al., 1999, 2003; Bruserud et al., 2005). The cell lines were 
differentiated into mature osteoblasts using a similar protocol to 
the one used for mouse primary osteoblasts. Efficient shRNA 
knockdown clones for Fra-2 were selected for each cell line and 
characterized using qPCR and Western blotting analyses (Fig. 6 B 
and not depicted). Importantly, all cell lines selected for shRNA 
control were able to differentiate into mature and functional osteo-
blasts as shown by Alizarin red staining (Fig. 6 B). Interest-
ingly, decreased Fra-2 levels inhibited osteoblast differentiation 
in all three cell lines (Fig. 6 B). Importantly, consistent with our 
previous findings, Fra-2 knockdown induced adipocyte differentia-
tion (Fig. 6 B and not depicted). In addition, Runx2, col12, and 
Oc mRNA levels were found to be strongly decreased in Fra-2 
knockdown clones at day 15 of differentiation in all three cell 
lines (Fig. 6 C and not depicted), whereas AP, Bsp, and col11 
mRNA levels were unaffected (Fig. 6 C). The cell number of 
Fra-2 knockdown clones was slightly increased after 12 d in cul-
ture (Fig. 6 D). These experiments strongly support our findings 
in the mouse that Fra-2 expression controls osteoblast differen-
tiation likely caused by altered expression of osteoblast-specific 
genes Oc and col12 in both murine and in human cells.
Discussion
The results presented in this study reveal a novel function of 
Fra-2/AP-1 in skeletal biology, particularly in bone-forming   
osteoblasts. Mesenchyme-derived osteoblasts are responsible for 
extracellular matrix deposition in bone. Their activity is deter-
mined by precursor cell proliferation and differentiation and by 
the bone-forming activity of mature osteoblasts. Fos/AP-1 pro-
teins, such as Fra-1 and FosB, were previously found to be 
regulators of bone mass by affecting bone matrix production 
and osteoblast activity (Jochum et al., 2000; Sabatakos et al., 
2000; Kveiborg et al., 2002; Eferl et al., 2004). Regarding the 
role of Fra-2 in skeletal biology, Fra-2 was known to regulate 
osteoclast  formation/survival  and  chondrocyte  differentiation 
(Karreth et al., 2004; Bozec et al., 2008). Here we show that 
Fra-2 is a key regulator in osteoblast differentiation.
The failure of Fra-2–deficient osteoblasts to mature and 
instead to acquire an adipogenic phenotype is remarkable. Loss 
of differentiation is accompanied by a decrease in expression   
of the osteoblast-specific Oc gene and reduced expression of 
col12. Oc, a -carboxyglutamic acid–containing noncollage-
nous protein, is a major component of bone extracellular matrix 
and is thought to be required to stimulate bone mineral matura-
tion (Boskey, 1998). The expression of Oc has also been shown   
to be controlled by Runx2, an early molecular marker of the osteo-
blast lineage (Ducy and Karsenty, 1995; Ducy et al., 1996a). 
Runx2 expression was found to be decreased in Fosl2 ko bones 
and in primary osteoblasts. However, 5 kb of promoter 1 as well 
as the intron1-2 defined as promoter 2 of Runx2 were analyzed, 
and no binding of Fra-2 to the Runx2 promoter could be de-
tected by ChIP experiment (unpublished data), indicating that 
loss of Fra-2 likely affects Runx2 expression indirectly. We can-
not exclude that decreased Runx2 levels contribute to impaired 
expression of Oc in cooperation with Fra-2/ATF-4. Moreover, 
Runx2 could possibly affect the “switch” between osteoblasts 
and adipocytes in the loss-of-function experiments. Runx2 is   JCB • VOLUME 190 • NUMBER 6 • 2010   11021103 Fra-2/AP-1 and bone mass regulation • Bozec et al.
involved in regulating the reciprocal differentiation pathway 
of  osteoblast  and  adipocyte  lineages.  Runx2
/  osteoblasts 
differentiated into adipocytes at high frequency (Kobayashi   
et al., 2000). It is known that Runx2 deficiency in chondrocytes 
causes adipogenic changes in vitro (Enomoto et al., 2004). 
Moreover, PPAR­ can regulate Runx2 and vice versa, although 
other independent pathways can regulate this factor, such as 
TGF- or adipocytokines.
ATF-4, a basic leucine zipper protein capable of dimeriza-
tion with Fos proteins, has been shown to be the second major   
determinant of osteoblast-specific expression of Oc (Yang   
et al., 2004). In this study, we demonstrate that Fra-2 dimerizes 
with ATF-4 to activate the Oc promoter in cell lines and primary 
osteoblasts. In the absence of Fra-2, ATF-4–containing dimers 
bound to the OSE1 site are greatly decreased, whereas the chro-
matin is enriched in inactive methylation marks. Fra-2 was not 
present on every ATF-4 target site, e.g., on the Rankl promoter, 
and Rankl expression was also not affected by loss of Fra-2. 
Interestingly, Oc expression was also found to be decreased in 
mice lacking JunB and Fra-1 (Eferl et al., 2004; Kenner et al., 
2004). However, JunB, like Fra-1, was not able to bind to the 
Oc promoter.
Although gene deletion studies have demonstrated the   
importance of Oc in bone remodeling, Oc deficiency does not 
result in low bone mass (Ducy et al., 1996a,b). Therefore,   
decreased expression of Oc alone cannot explain the dramatic 
bone loss observed in Fra-2 ko pups. The exclusive coexpres-
sion in osteoblasts of AP, an enzyme that cleaves pyrophos-
phate, and col1, the most abundant and most widely distributed 
collagen  type,  is  necessary  and  sufficient  for  extracellular   
matrix mineralization to occur in bone (Murshed et al., 2005). Col1 
consists of two 1(I) chains and one 2(I) chain encoded by 
two different genes. We did not observe any changes in AP or in 
col11 expression. However, there was a marked reduction of 
col12 RNA in Fosl2 ko cells and a marked increase in Fosl2 tg 
long bones. The transcription of the 2(I) collagen gene involves 
known, but also yet to be identified, DNA sequences located in 
both  the  proximal  promoter  and  a  far  upstream  enhancer 
(Karsenty and Park, 1995). AP-1 has been implicated in the 
transcriptional  regulation  of  both  the  mouse  and  the  human 
2(I) collagen genes by TGF- (Chang and Goldberg, 1995; 
Chung et al., 1996). Fra-2 was found to bind and activate the 
col12 promoter through a novel AP-1 binding element, and   
c-Jun and JunB are potential dimerization partners. Consistent 
with this finding, mice deficient for JunB develop a severe   
osteopenia with markedly reduced col12 levels (Kenner et al., 
2004). In addition, a recent publication has shown that TGF- 
activates the human col12 gene via a noncanonical signaling, 
which requires c-Jun or JunB transcription factor occupancies 
in fibroblasts (Ponticos et al., 2009). The identification of 
col12 as a direct Fra-2/AP-1 target gene in osteoblasts estab-
lishes that AP-1 controls expression of essential extracellular 
matrix components. This is further substantiated by the fact that 
we show for the first time total collagen content of osteoblasts 
regulated by Fra-2.
We  have  recently  shown  that  bones  of  Fra-2–deficient 
newborn mice have giant osteoclasts, and the pups are osteo-
penic (Bozec et al., 2008). Notably, Opn was found up-regulated   
in Fra-2 ko pups, which may reflect the fact that these mutants 
exhibit a giant osteoclast phenotype. Moreover, the data pre-
sented here strongly imply that the osteopenia is caused by a 
combination of cell-autonomous effects of Fra-2 on both the 
osteoblast and osteoclast lineages. The number and activity of 
osteoclasts remained unchanged in Fra-2 tg mice in vivo, and 
Rankl, OPG, as well as CTx levels in the blood were unaffected. 
However, increased bone resorption activity and marker gene 
expression were observed during osteoclast differentiation   
in vitro. These data suggest that Fra-2 is apparently not necessary 
for osteoclast differentiation in vivo and that signals from the 
bone surface might affect osteoclast activity, which is missing 
in in vitro cultures. In Fra­1–deficient mice, the low bone mass 
phenotype was reported to be a result of defects in the late mat-
uration of osteoblasts to bone matrix–producing cells accompa-
nied by insufficient induction of the bone matrix components 
Mgp, Oc, and col12. Up-regulation of Oc and col12 expres-
sion was less pronounced in bones of Fra-1 tg mice compared 
with Mgp (Eferl et al., 2004), which is directly regulated by 
Fra-1 (Julien et al., 2009). In this study, we did not detect any 
binding of Fra-1 to the Oc or col12 promoters, suggesting that 
Fra-2 might be the major AP-1 factor directly regulating this 
important collagen component. Moreover, Fra-2 and FosB, 
unlike Fra-1, exert distinct effects on both osteoblastic and adi-
pocyte differentiation in vitro (Kveiborg et al., 2002; Eferl et al., 
2004). CEBP- was found similarly regulated in FosB and 
Fra-2 tg long bones. In fact, differentiation of mesenchymal 
cells into adipocytes involves a cascade of transcription factors, 
such as CEBP- and CEBP-, which in turn activate PPAR-, 
an essential gene for the activation of several adipocyte-specific 
genes (Wu et al., 1995). Our data suggest that Fra-2 regulates 
adipocyte marker gene expression along with the expression of 
Oc, which is known to be important in metabolic function (Hinoi 
et al., 2008, 2009; Takeda and Karsenty, 2008).
Down-regulation of Fra-2 in human bone cell lines and bone 
tumors is accompanied by decreased osteoblast differentiation 
Figure 6.  Fra-2 affects human matrix protein expression in vivo and in vitro. (A) Immunohistochemistry for Fra-2, collagen1 (col1), and osteocalcin (Oc) 
in human bone normal tissue, chondrosarcoma, and osteoblastic Os. Arrows indicate Fra-2, col1, or Oc-positive staining for stromal cells in human bone 
sample. Bar, 100 µm. Inset bar, 50 µm. (B) qPCR analyses of Fra-2 at day 0 of differentiation in Cal72, SAOs, and U2Os human Os cell clones. Area of 
nodule formation quantification where shRNA control clones represent 100%. n = 3. Alizarin red staining (Cal72, SAOs, and U2Os) and Oil red O (U2Os) 
staining of control and Fra-2 knockdown human Os cells. Cells were cultured for 15 d on plastic in the presence of -glycerophosphate and ascorbic acid. 
(C) qPCR analyses of osteoblast markers Runx2, AP, bone sialoprotein (Bsp), collagen 11 (col1), collagen 12 (col12), and Oc at day 15 of differ-
entiation. Values are presented as relative expression, and wt is set to 100. (D) Cumulative cell number (proliferation) of U2Os shRNA control and U2Os 
shRNA Fra-2 clones. Error bars represent mean values ± SD. *, P < 0.01.
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culture, bone nodules were identified by Alizarin S red staining (Sigma-
  Aldrich), and adipocytes were identified by Oil red O staining.
Bone marrow cells were isolated from 6-wk-old mice, brought into 
suspension overnight, and then cultured in 24 wells at a density of 5 × 10
5 
cells/well, 20 ng/ml macrophage colony–stimulating factor (R&D Systems), 
and 5 ng/ml Rankl (R&D Systems) for 2–7 d.
Real-time PCR analyses
qPCR reactions were performed using SYBR green (Invitrogen) on an Opti-
con2 Monitor Fluorescence Thermocycler (MJ Research). The comparative 
CT method was used to quantify the amplified fragments. RNA expression 
levels were normalized to at least one housekeeping gene (tubulin, actin, 
and hprt), whereas chromatin-bound fragments were normalized to the 
same fragments amplified from input chromatin.
CTx measurements
CTx levels were determined in sera from mice fasting for 4 h before bleed-
ing using a commercial kit (RatsLap; Immunodiagnostic).
Collagen content
Collagen contents were analyzed in conditioned medium during osteoblast 
differentiation using the Sircoll procedure following the Sircoll kit instruc-
tions from Biocolor.
shRNA experiments
shRNA for Fra-2 and control (random sequence) virus were generated fol-
lowing the protocol from Sigma-Aldrich (Mission RNA). Primary or osteo-
blast cell lines were infected with the virus. shRNA knockdown clones for 
Fra-2 were selected for each cell line by puromycin and characterized by 
qPCR and Western blotting.
ChIP
ChIP was performed according to standard protocols with antibodies against 
Fra-2, Fra-1, c-Fos, JunB, JunD, c-Jun, ATF-4 (Santa Cruz Biotechnology, Inc.), 
K4 (Millipore), and K27 (gift from T. Jenuwein). The specific binding of each 
Jun and Fos antibody was verified in parallel using a corresponding pair   
of wt and ko osteoblasts and the Fosl1 canonical TRE element as a target   
sequence. Bound and unbound fragments were quantified by real-time PCR.
Reporter assay
The promoter–reporter vectors for Oc and col12 were gifts of G. Karsenty 
and B. de Combrugghe, respectively (Goldberg et al., 1992; Ducy et al., 
1996b). 6 × 10
4 Cos7 cells/well were plated in 24-well dishes. 1.5 µg of 
the  luciferase  reporter  construct,  0.2  µg  of  the  renilla  internal  control 
(pHRG-tk; Promega), and 0.2–1 µg of each AP-1 expression vector were 
cotransfected in triplicate using calcium phosphate (Bakiri et al., 2002). 
JunB–Fra-2, cJun–Fra-2, and ATF-4–Fra-2 forced dimer constructs were gen-
erated as previously described (Bakiri et al., 2002). Luciferase activity was 
quantified using the Dual Luciferase kit (Promega).
Statistical analysis
All experiments were repeated at least three times and done in triplicate. 
Statistical analysis was performed using a t test. P < 0.01 was accepted as 
significant. Data are shown as means, and the error bars represent SD.
Online supplemental material
Fig. S1 shows the osteoclast phenotype in Fosl2 tg mice. Fig. S2 shows 
that col12 and Oc are direct transcriptional targets of Fra-2 in primary 
osteoblasts. Fig. S3 shows Fra-2 and matrix protein expression in human 
samples.  Online  supplemental  material  is  available  at  http://www.jcb 
.org/cgi/content/full/jcb.201002111/DC1.
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with a switch to adipogenesis. This implies that the underlying 
molecular mechanism is conserved between mice and humans. 
The relevance of these findings for osteoporosis and human 
bone mass regulation is supported by preliminary data demon-
strating coexpression and possible coregulation of Fra-2, Oc, 
and col1 in human Os’s of osteoblastic and chondrogenic ori-
gin, both in vivo and in vitro. Chondroblastic Os is the most 
common primary malignancy of the skeleton and comprises 
25% of all cases of Os (Li and Siegal, 2010). Because treat-
ment and prognosis are very different for chondroblastic Os’s 
compared with giant cell tumors of bone, it is important to have 
a  reliable  assay  to  distinguish  between  these  different  bone   
tumors (Fox et al., 2009). Although our results are preliminary, 
we would like to suggest that coexpression of Fra-2, col1, and 
Oc in certain Os’s might possibly be used as a diagnostic tool. 
In summary, this study has identified Fra-2 as a novel regulator 
of bone matrix production and osteoblast differentiation, which 
presents a novel paradigm to modulate bone mass and could be 
considered for the development of future therapeutic strategies 
for diseases involving bone loss.
Materials and methods
Mice and tissue fixation
The generation of Fosl2
/ and Fosl2 tg mice has been described previ-
ously (Eferl et al., 2007, 2008). All mice were maintained on a mixed 
C57BL6/129 background.
RNA isolation and reverse transcription
Total RNA was isolated with the TRIZOL protocol (Invitrogen). cDNA syn-
thesis was performed using 2 µg RNA with the Ready To Go You Prime It 
First-Strand Beads and random primers (GE Healthcare) according to the 
manufacturer’s protocols.
Histological analysis and histomorphometry
Mice were killed by CO2 asphyxia, and bones were fixed in 3.7% PBS-
buffered formaldehyde. For histological and in situ hybridization analysis, 
bones were embedded in paraffin. For histomorphometrical analysis, un-
decalcified tibiae and lumbar spines were embedded in methylmethacry-
late, and 5-µm sections were cut in the sagittal plane. Sections were stained 
with toluidine blue and modified von Kossa/van Gieson. Quantitative his-
tomorphometry was performed on toluidine blue–stained sections accord-
ing to standardized protocols (Parfitt et al., 1987) using the Osteomeasure 
histomorphometry system (Osteometrix). Experiments were performed in a 
blinded fashion.
In situ hybridization and immunohistochemistry
Immunohistochemistry stainings for Fra-2 (Abcam), col1 (Santa Cruz Bio-
technology, Inc.), and Oc (Santa Cruz Biotechnology, Inc.) were performed 
on deparaffinized sections using the labeled streptavidin-biotin or Envision 
detection kit (Dako). For in situ hybridization, digoxigenin-labeled ribo-
probes were synthesized according to the manufacturer’s instructions (DIG 
RNA labeling kit; Boehringer Ingelheim). The signal was detected using 
BM purple–AP-substrate solution according to the manufacturer’s (Boeh-
ringer Ingelheim) instructions. Sections were then washed, fixed in 4% PFA, 
and mounted. Pictures were taken using a microscope (DM3000; Leica) 
with 40x (oil; NA 1.25–0.75), 20x (no medium; NA 0.70), and 10x (no 
medium; NA 0.15) objectives (Plan Apochromat) outfitted with a charge-
coupled device camera at a temperature of 24°C and Leica Application 
Suite Image Acquisition and Analysis software.
Osteoblast and osteoclast cultures
Calvariae were sequentially digested for 10 min in modified MEM type  
containing 0.1% collagenase and 0.2% dispase. Cells isolated by frac-
tions 2–3 were combined as an osteoblastic cell population, expanded for 
2 d in MEM type  with 10% FCS, and replated at a density of 5 × 10
5 
cells/well, and medium was supplemented with 10 mM -glycerophos-
phate and 50 µg/ml ascorbic acid (Eferl et al., 2004). After 3 wk of   1105 Fra-2/AP-1 and bone mass regulation • Bozec et al.
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